Showing results (211-220 of 255) with videos related to
Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2017
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 LevelsJames N Kochenderfer, Robert P T Somerville, Tangying Lu, et al.British Journal of Haematology|September 8, 2015
Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraCatherine S Diefenbach, Hailun Li, Fangxin Hong, et al.Blood Advances|November 27, 2024
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO ConsortiumJonathan R Day, Melissa C Larson, Urshila Durani, et al.British Journal of Haematology|December 20, 2016
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106Robert W Chen, Hongli Li, Steven H Bernstein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 14, 2020
Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001Daniel O Persky, Hongli Li, Deborah M Stephens, et al.The Lancet. Haematology|December 4, 2018
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 studyKieron Dunleavy, Michelle A Fanale, Jeremy S Abramson, et al.Leukemia & Lymphoma|January 11, 2019
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysisZeina Al-Mansour, Hongli Li, James R Cook, et al.The New England Journal of Medicine|November 1, 2013
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphomaPatrick J Stiff, Joseph M Unger, James R Cook, et al.Blood Cancer Journal|August 1, 2025
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-upEva Domingo-Domènech, Barbara Pro, Tim Illidge, et al.Blood Advances|January 4, 2018
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HLMonika Pilichowska, Stefania Pittaluga, Judith A Ferry, et al.Pageof 26